Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/26/a8/1c/26a81ca2-e6c2-3106-c0ea-4f34739538a7/mza_5720169948074697845.jpg/600x600bb.jpg

Biotech Blueprint

Katerina Roznik

35 episodes

4 days ago

Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs. For more content, please subscribe to biotechblueprint.substack.com.

Technology

RSS

All content for Biotech Blueprint is the property of Katerina Roznik and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Technology

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/43595577/43595577-1746303445394-91295cd6263e8.jpg

Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build — This Week in Biotech #76

Biotech Blueprint

3 minutes 46 seconds

4 weeks ago

Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build — This Week in Biotech #76

Subscribe to Biotech Blueprint newsletter for free at biotechblueprint.com.